Literature DB >> 22282432

Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin.

R L Carhart-Harris1, R Leech, T M Williams, D Erritzoe, N Abbasi, T Bargiotas, P Hobden, D J Sharp, J Evans, A Feilding, R G Wise, D J Nutt.   

Abstract

BACKGROUND: Psilocybin is a classic psychedelic drug that has a history of use in psychotherapy. One of the rationales for its use was that it aids emotional insight by lowering psychological defences. AIMS: To test the hypothesis that psilocybin facilitates access to personal memories and emotions by comparing subjective and neural responses to positive autobiographical memories under psilocybin and placebo.
METHOD: Ten healthy participants received two functional magnetic resonance imaging scans (2 mg intravenous psilocybin v. intravenous saline), separated by approximately 7 days, during which they viewed two different sets of 15 positive autobiographical memory cues. Participants viewed each cue for 6 s and then closed their eyes for 16 s and imagined re-experiencing the event. Activations during this recollection period were compared with an equivalent period of eyes-closed rest. We split the recollection period into an early phase (first 8 s) and a late phase (last 8 s) for analysis.
RESULTS: Robust activations to the memories were seen in limbic and striatal regions in the early phase and the medial prefrontal cortex in the late phase in both conditions (P<0.001, whole brain cluster correction), but there were additional visual and other sensory cortical activations in the late phase under psilocybin that were absent under placebo. Ratings of memory vividness and visual imagery were significantly higher after psilocybin (P<0.05) and there was a significant positive correlation between vividness and subjective well-being at follow-up (P<0.01).
CONCLUSIONS: Evidence that psilocybin enhances autobiographical recollection implies that it may be useful in psychotherapy either as a tool to facilitate the recall of salient memories or to reverse negative cognitive biases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22282432     DOI: 10.1192/bjp.bp.111.103309

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  40 in total

Review 1.  Molecular brain imaging in the multimodality era.

Authors:  Julie C Price
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

Review 2.  REBUS and the Anarchic Brain: Toward a Unified Model of the Brain Action of Psychedelics.

Authors:  R L Carhart-Harris; K J Friston
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 3.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

Review 4.  The acute effects of classic psychedelics on memory in humans.

Authors:  C J Healy
Journal:  Psychopharmacology (Berl)       Date:  2021-01-09       Impact factor: 4.530

5.  Role of psilocybin in the treatment of depression.

Authors:  Ananya Mahapatra; Rishi Gupta
Journal:  Ther Adv Psychopharmacol       Date:  2016-10-27

6.  The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms.

Authors:  Frederick S Barrett; Matthew P Bradstreet; Jeannie-Marie S Leoutsakos; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-11-17       Impact factor: 4.153

7.  Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Authors:  Albert Garcia-Romeu; Roland R Griffiths; Matthew W Johnson
Journal:  Curr Drug Abuse Rev       Date:  2014

Review 8.  The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future.

Authors:  Robin L Carhart-Harris; Guy M Goodwin
Journal:  Neuropsychopharmacology       Date:  2017-04-26       Impact factor: 7.853

9.  Mind-altering drugs and research: from presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on "Drugs and Science".

Authors:  David Nutt
Journal:  EMBO Rep       Date:  2014-02-14       Impact factor: 8.807

10.  LSD alters eyes-closed functional connectivity within the early visual cortex in a retinotopic fashion.

Authors:  Leor Roseman; Martin I Sereno; Robert Leech; Mendel Kaelen; Csaba Orban; John McGonigle; Amanda Feilding; David J Nutt; Robin L Carhart-Harris
Journal:  Hum Brain Mapp       Date:  2016-04-29       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.